AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00627692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT02907229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCVC-CS1
Description: Intervention Description
Study NCT00997893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Phytoestrogen
Description: Novasoy® pill (55 mg)
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol pill (1 mg)
Study NCT03464136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Ustekinumab
Description: Participants will receive placebo as SC injection to blind adalimumab.
Study NCT03464136 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Adalimumab
Description: Participants will receive placebo as IV infusion to blind ustekinumab.
Study NCT03464136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg)
Description: Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
Study NCT03464136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg)
Description: Participants will self-administer SC injection of ustekinumab 90 mg.
Study NCT03464136 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (40 mg)
Description: Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
Study NCT01751347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetics
Study NCT01751347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local anesthetics
Study NCT03500848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
Study NCT03500848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tacrolimus elimination)
Description: Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
Study NCT03500848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
Study NCT03500848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF and/or steroids
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
Study NCT03500848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF and/or steroids
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
Study NCT02347670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy-patient navigator to improve follow-up adherence
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
Study NCT02347670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office-Based Usual Care
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital.
Study NCT05308043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning algorism
Description: A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
Study NCT02437149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
Study NCT02437149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power Point
Description: Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
Study NCT02437149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure with the National Highway Traffic Safety Administration information about distracting driving.
Study NCT00868309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anavip
Description: Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
Study NCT00868309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CroFab
Description: CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
Study NCT03165565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)
Description: Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
Study NCT03165565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
Study NCT03137563 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
Study NCT00349947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
Study NCT05231109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vestibular rehabilitation
Description: Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
Study NCT04957108 — intervention group
Intervention type: OTHER
Intervention: Device identification using Xray.
Description: PMIDa and CRMD-f applications were used to identify CIED
Study NCT02287168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid before gastrectomy
Study NCT02287168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid after gastrectomy
Study NCT02287168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-lavage peritoneal washing cytology
Description: sampling of peritoneal washing fluid after peritoneal lavage
Study NCT02276196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: GLP-1 receptor agonist
Study NCT02276196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Insulin analogue
Study NCT04259840 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements
Study NCT01506830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relative isolation with cotton rolls
Description: Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
Study NCT01506830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation with rubber dam
Description: Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
Study NCT00041574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
Study NCT01202006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of general practitioners in an uptitration protocol.
Description: The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
Study NCT02396381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2
Description: Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
Study NCT02396381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Ad libitum use of CC in an ambulatory setting for 26 weeks
Study NCT01621425 — intervention group
Intervention type: OTHER
Intervention: Lean body mass
Description: Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
Study NCT01621425 — intervention group
Intervention type: OTHER
Intervention: Total body weight
Description: Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
Study NCT01621425 — intervention group
Intervention type: OTHER
Intervention: bloodsampling
Description: Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
Study NCT01904786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT01904786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00719784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Response Imaging
Description: Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
Study NCT01290263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amgen 386
Description: For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.
Study NCT01290263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
Study NCT03169959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Saxagliptin tablet
Description: A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00105001 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study NCT00105001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study NCT00105001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00105001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00105001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00105001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00105001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT04028089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Modification Group
Description: The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
Study NCT04028089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular Diet Group
Description: Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study.
Study NCT03475277 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Acute administration
Study NCT02610907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffer
Description: The sleeve contains phosphate buffered saline buffer
Study NCT02610907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own output
Description: The sleeve contains the subject own ileal effluent
Study NCT02610907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated output
Description: The sleeve contains simulated output
Study NCT02004470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active lavage and suction
Description: Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
Study NCT02718430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Oral immunotherapy targeting VEGFR2
Study NCT00699049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha blocker
Description: oral
Study NCT00699049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha blocker
Description: oral
Study NCT00699049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT00699049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study NCT01699503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Dementia Care Program
Description: Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
Study NCT04237168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgNGS from circulating tumor DNA
Description: 3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
Study NCT00639782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Heart valve replacement
Description: On-X Heart valve replacement
Study NCT00639782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SJM Heart valve replacement
Description: SJM Heart valve replacement
Study NCT01534689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia FX-405™ Laser
Description: The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (MPA)
Description: medroxyprogesterone acetate (MPA) (10mg)
Study NCT00997893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Placebo
Description: oral placebo pill (0mg Soy Phytoestrogen)
Study NCT02156726 — intervention group
Intervention type: DRUG
Intervention: low-dose FCR
Description: FCR with attenuated dose of fludarabine and cyclophosphamide
Study NCT03492944 — intervention group
Intervention type: DRUG
Intervention: Ultrasound Microbubble Contrast Agent
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
Study NCT03492944 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
Study NCT03026192 — intervention group
Intervention type: DEVICE
Intervention: near infrared spectroscopy
Description: Near infrared spectroscopy will be placed on infants both with and without hsPDA
Study NCT04317365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Women receiving extra remembering by healthcare
Description: Women receiving extra remembering by healthcare in covid infection
Study NCT01389505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation
Description: Three episodes of panretinal photocoagulation with one week of interval
Study NCT01389505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab
Description: Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP